Latest Conference Articles

Dr. Garcia-Sanz on Brentuximab Vedotin Plus ESHAP in Hodgkin Lymphoma

Ramon Garcia-Sanz, MD, PhD, clinician, department of Hematology, Hospital Universitario de Salamanca, discusses the results of brentuximab vedotin (Adcetris) plus ESHAP followed by autologous stem cell transplant in patients with relapsed/refractory Hodgkin lymphoma.

Dr. Prockop Discusses Tabelecleucel in Post-Transplant EBV+ Lymphomas

Susan E. Prockop, MD, pediatric oncologist, Memorial Sloan Kettering Cancer Center, discusses tabelecleucel in patients with Epstein-Barr virus (EBV)-associated post-transplant lymphomas.

PET-Guided De-escalation Effective in Advanced Hodgkin Lymphoma

PET can be safely used to guide treatment in patients with untreated advanced-stage classical Hodgkin lymphoma after 2 cycles of upfront de-escalated BEACOPP.

Obinutuzumab/Chlorambucil Solidified as Frontline CLL Option

The combination of obinutuzumab and chlorambucil reduced the risk of death by 24% versus rituximab plus chlorambucil in treatment-naïve patients with chronic lymphocytic leukemia with comorbidities.

Frontline Atezolizumab Regimen Improves Survival for NSCLC

The combination of atezolizumab, bevacizumab, carboplatin, and paclitaxel educed the risk of death by 22% compared with bevacizumab and chemotherapy in patients with advanced wild-type non-squamous non–small cell lung cancer.

Dr. Lopes on the KEYNOTE-042 Results of Frontline Pembrolizumab in NSCLC

Gilberto Lopes, MD, a medical oncologist at the Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses findings from the KEYNOTE-042 trial of frontline pembrolizumab (Keytruda) as a treatment for patients with squamous and nonsquamous non–small cell lung cancer in an interview with OncLive during the 2018 ASCO Annual Meeting.

Dr. Drilon Discusses Efficacy Results With LOXO-292 in RET-Altered Solid Tumors

Alexander Drilon, MD, medical oncologist, clinical director, Early Drug Development Service, Memorial Sloan Kettering Cancer Center, discusses findings from the phase I LIBRETTO-001 study exploring the highly selective RET inhibitor LOXO-292 in patients with RET-altered solid tumors.

Chemoprevention Reduces Risk for Esophageal Cancer

A combination of 2 over-the-counter medicines can moderately reduce the risk for high-grade dysplasia or esophageal cancer in patients with Barrett’s esophagus if taken for at least 7 years.

NKTR-214/Nivolumab Efficacy Sustained in Phase II Findings

Combining the CD122-biased cytokine NKTR-214 with the PD-1 inhibitor nivolumab (Opdivo) showed promising antitumor activity, particularly in PD-L1–negative patients.

Pancreatic Cancer Survival Jumps With Postsurgical Chemo Combo

A 4-drug chemotherapy combination dramatically improved survival compared with standard gemcitabine as postoperative therapy for patients with resected pancreatic cancer.

Cemiplimab Reaches Near 50% Response in Metastatic CSCC

The PD-1 inhibitor cemiplimab induced an overall response rate of 47.5% in patients with metastatic cutaneous squamous cell carcinoma.

Neoadjuvant Chemoradiotherapy May Improve OS Over Adjuvant Standard-of-Care in Pancreatic Cancer

Preoperative treatment with chemotherapy and radiation improved overall survival rates for patients with resectable or borderline resectable pancreatic cancer compared with immediate surgery.

Heated Chemo During Resection Shows No Benefit in Advanced CRC

The addition of heated chemotherapy delivered to the abdomen during surgery delivered no survival benefit to patients with peritoneal carcinomatosis.

Liso-Cel Shows Durable CRs for High-Risk DLBCL

Lisocabtagene maraleucel (JCAR017; liso-cel) demonstrated a durable complete remission rate of 46% at 6 months for patients with high-risk diffuse large B-cell lymphoma.

CD22 Immunotoxin Achieves Durable Complete Remissions in Relapsed Hairy Cell Leukemia

Moxetumomab pasudotox, a first-in-class recombinant immunotoxin targeting CD22, produced deep and durable responses in a substantial proportion of pretreated patients with relapsed/refractory hairy cell leukemia.

Dr. Jotte on the IMpower131 Findings in Squamous NSCLC

Robert M. Jotte, MD, PhD, medical director and co-chair, USON Thoracic Committee, Rocky Mountain Cancer Centers, discusses the phase III findings of the IMpower131 trial, which looked at the addition of atezolizumab (Tecentriq) to frontline carboplatin and nab-paclitaxel (Abraxane) in patients with advanced squamous non

Rituximab/Lenalidomide Potential Frontline Therapy for Follicular Lymphoma

Similar efficacy with the combination of rituximab and lenalidomide coupled with a better safety profile compared with rituximab plus chemotherapy may make the chemo-free regimen a new frontline option for patients with previously untreated follicular lymphoma.

Dr. Slamon on the Phase III Results of MONALEESA-3 Trial in HR+/HER2- Breast Cancer

Dennis J. Slamon, MD, PhD, director, Clinical/Translational Research, Revlon/University of California, Los Angeles (UCLA) Women's Cancer Research Program, Jonsson Comprehensive Cancer Center, UCLA, discusses findings of the phase III MONALEESA-3 trial evaluating ribociclib (Kisqali) plus fulvestrant (Faslodex) in postmenopausal women with hormone receptor (HR)-positive, HER2-negative advanced breast cancer.

Anti-CD47 Antibody Plus Rituximab Demonstrates Efficacy in Half of Patients With Relapsed/Refractory NHL

Half of a small group of patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) had major responses to treatment with an anti-CD47 antibody plus rituximab (Rituxan).

Pegilodecakin Plus PD-1 Inhibitor Shows Potential in NSCLC

Combining pegilodecakin with nivolumab or pembrolizumab induced an overall response rate of 41% in patients with advanced non–small cell lung cancer.

Frontline Ibrutinib/Venetoclax Combo Shows High MRD-Negative Responses for CLL

The frontline combination of ibrutinib and venetoclax demonstrated a 100% objective response rate for patients with chronic lymphocytic leukemia, with 77% of patients testing negative for minimal residual disease in the peripheral blood after 6 cycles.

Erdafitinib Active in Advanced Metastatic Urothelial Carcinoma

More than 40% of patients with metastatic or unresectable urothelial carcinoma responded to treatment with an investigational fibroblast growth factor receptor inhibitor.

Early OS Data Support Phase III Trial With AKT Inhibitor Ipatasertib for TNBC

First-line treatment with the oral AKT inhibitor ipatasertib shows a promising trend toward improving overall survival when added to paclitaxel for the treatment of locally advanced or metastatic triple-negative breast cancer.

Ribociclib Prolongs PFS With Fulvestrant in First- or Second-Line HR-Positive, HER2-Negative Advanced Breast Cancer

Adding the CDK4/6 inhibitor ribociclib to fulvestrant significantly prolonged progression-free survival in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received no or 1 prior line of therapy.

Lenvatinib-Pembrolizumab Combo Has Promising Activity in Squamous Cell Head and Neck Cancer

Lenvatinib added to pembrolizumab demonstrated promising activity in patients with squamous cell carcinoma of the head and neck in an ongoing open-label phase Ib/II clinical trial.

Pembrolizumab Plus Chemo Emerges as New Standard in Frontline Squamous NSCLC

Adding pembrolizumab to frontline carboplatin/paclitaxel or nab-paclitaxel reduced the risk of death by 36% compared with chemotherapy alone in patients with metastatic squamous non–small cell lung cancer.

Endocrine Therapy Alone Is Sufficient in HR+/HER2- Breast Cancer With Intermediate Recurrence Score

Adjuvant endocrine therapy alone is noninferior to adjuvant chemoendocrine therapy in patients with hormone receptor–positive, HER2-negative, node-negative early-stage breast cancer.

Sunitinib Noninferior to Surgery for OS in Metastatic Kidney Cancer

Sunitinib alone was noninferior to cytoreductive nephrectomy plus sunitinib, the current standard of care, in patients with synchronous metastatic renal cell carcinoma.

Maintenance Therapy Changes Paradigm in Rare Childhood Sarcoma

A course of low-dose maintenance chemotherapy administered after standard-of-care intensive chemotherapy led to significant improvements in disease-free and overall survival in pediatric rhabdomyosarcoma.

Frontline Pembrolizumab Bests Chemo in NSCLC, Especially in PD-L1-High Subgroup

Patients with non-small cell lung cancer treated with frontline pembrolizuma lived 4 to 8 months longer than those who received standard of care chemotherapy.